Month: March 2026

EfTEN United Property Fund earned a net profit of 131 thousand euros in February 354 thousand euros in first two months of 2026 (the same period last year: 525 thousand euros). The net asset value (NAV) of the fund unit was 11,9 euros at the end of February, increasing by 0,4% per month. Invego Uus-Järveküla OÜ, a development company in which the fund has an 80% stake, concluded 12 real rights contracts in February and clients booked 2 terraced houses. As of the end of the month, a total of 8 terraced houses had not yet been reserved by clients. In February, EfTEN United Property Fund earned 17 thousand euros in interest income from the investment and the development company earned 615 thousand euros of profit. As EfTEN United Property Fund values all equity investments at fair value, the February profit from the Uus-Järveküla development...

Press contactFahd PashaTel.: +1 647 860 3777Fahd.Pasha@capgemini.com 85% of banks’ corporate clients plan to engage with a non-bank financial institution within the next year as competition with private capital intensifiesBanks look to bolster AI expertise with external hires (40%) as upskilling proves challenging Only 29% of IT budgets are currently directed to transformative technologies Corporate Investment Banks executives bet on tokenized products (51%) to improve performanceParis, March 16, 2026 – Corporate and investment banks (CIBs) are facing intense competition from non‑bank financial institutions, as client expectations rise and technology initiatives fail to deliver the anticipated benefits, according to the Capgemini Research Institute’s inaugural World Corporate and Investment Banking Report 2026. The research shows...

Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Tecan presents 2025 results and provides details on program to reignite profitable growth Financial results for the full year 2025 – SummarySales of CHF 882.5 million (2024: CHF 934.3 million), down 1.6% in local currencies for the year, with second-half sales growth of 0.4% Order entry increased by 3.8% in local currencies for the full year and by 8.6% in the second half Adjusted EBITDA of CHF 142.1 million (2024: CHF 164.4 million), adjusted EBITDA margin of 16.1% (2024: 17.6%), impacted by adverse foreign exchange effects and tariffs, partly offset by cost-reduction measures and underlying improvements Net profit impacted by non-cash impairment charges of CHF 139.5 million resulting in a reported net loss of CHF 110.7 million (2024: net profit...

BEIJING, March 15, 2026 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first healthy volunteer has been dosed in a clinical trial of ICP-538, a VAV1-directed molecular glue degrader (MGD), in China. This is the first VAV1 degrader approved to enter clinical trials in China and the second globally. ICP-538 is a novel, potent, highly selective, orally administered molecular glue degrader targeting VAV1, a key protein downstream of T-cell and B-cell receptors. ICP-538 induces rapid and efficient degradation of VAV1 protein in a dose-dependent manner by selectively mediating the formation of a ternary complex between the CRBN E3 ubiquitin ligase and the VAV1 protein. ICP-538 will be developed for...

Perth, Western Australia, March 16, 2026 (GLOBE NEWSWIRE) — PERSEUS ANNOUNCES SALE OF GROUP INTEREST IN MEYAS SAND PROJECT IN SUDAN HIGHLIGHTSPerseus has signed a Share Purchase Agreement (SPA) to sell its 70% group interest in the Meyas Sand Project (MSGP) located in Sudan to Hong Kong Matrix Golden Fortune Mining Limited (Buyer), a wholly owned subsidiary of Matrix Resources (Zhejiang) Co., Ltd. (together with its subsidiaries, the “Matrix Group”), for a cash consideration of US$260M. Purchase price comprises a US$10M deposit received on signing of the SPA and US$250M payable on completion of the transaction which is to occur on April 22, 2026. Proceeds will further strengthen Perseus superior balance sheet along with consideration of additional capital returns to shareholders.Perth, Western Australia/ March 16, 2026/...

MELBOURNE, Australia and INDIANAPOLIS, March 16, 2026 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces the resubmission of a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX101-Px, (Pixclara®1, Floretyrosine F 18 or 18F-FET), an investigational PET2 imaging agent for the characterization of recurrent or progressive glioma (brain cancer) from treatment related changes in both adult and pediatric patients. Telix has resubmitted the NDA with the additional data requested by the FDA. The Company believes, based on the Type A meeting and ongoing consultation with the FDA, that the additional data and statistical analysis, along with the primary data set provided in the original submission, appropriately addresses the Complete Response Letter3. Given...

The Annual General Meeting of Iceland Seafood International hf will be held on Tuesday 24 March 2026 at 4pm at Hilton Reykjavík Nordica, Suðurlandsbraut 2, 108 Reykjavik, Iceland.  The meeting will be in Icelandic. Enclosed is the final agenda for the Annual General Meeting 2026 and final proposals. No changes have been made neither to the proposals nor the agenda since the meeting was convened. Information and documents for the Annual General Meeting can be found on the company’s website: Annual General Meeting (icelandseafood.com)AttachmentsISI_AGM_Notice to convene the AGM 2026ISI_AGM_Board Proposals 2026

New data shows positive real-world impact of the world’s first and only one-year CGM, with a full year of strong patient adherence, glucometrics and hypoglycemic outcomes Eversense 365 delivered comparable adherence and outcomes between the first and second six-month period, indicating high accuracy and performance from a single sensor across an entire year GERMANTOWN, Md., March 14, 2026 (GLOBE NEWSWIRE) — Senseonics, a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes, today announces new data from a real-world evidence study which demonstrates the sustained performance and positive impact of Eversense 365 across the full one-year period. These findings were presented during an oral presentation...